Epilepsy Pipeline Assessment Report Covering the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

May 04 19:21 2023
Epilepsy Pipeline Assessment Report Covering the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 90+ pipeline drugs in the Epilepsy therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Epilepsy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Epilepsy Market. 

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Epilepsy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Epilepsy and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral 

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer 

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Epilepsy Therapeutic Segment @


Epilepsy Therapeutics Landscape

There are approx. 75+ key companies are developing therapies for Epilepsy. Currently, SK Life Science is leading the therapeutics market with its Epilepsy drug candidates in the most advanced stage of clinical development.

The Leading Players in the Epilepsy Therapeutics Market Include:

  • UCB

  • SK Life Science

  • Stoke Therapeutics

  • Xenon Pharmaceuticals

  • Epygenix

  • Bright Minds Biosciences

  • Neurona Therapeutics

  • Cevevel Therapeutics

  • PTC Therapeutics

  • Addex Pharmaceuticals

  • Equilibre Biopharmaceuticals B.V.

  • ES Therapeutics Australia Pty Ltd

  • Overseas Pharmaceuticals

  • Anavex Life Sciences

  • Eliem Therapeutics

  • Ovid Therapeutics

  • CAMP4 Therapeutics

  • LifeSplice

  • Virpax Pharmaceuticals

  • Neuroene Therapeutics

And Many Others

Epilepsy Emerging and Marketed Drugs Covered in the Report Include

  • ZX008 (Fenfluramine Hydrochloride): UCB

  • Cenobamate: SK Life Science, Inc.

  • STK-001: Stoke Therapeutics

  • EPX-100: Epygenix

  • NRTX-1001: Neurona Therapeutics 

  • BMB-101: Bright Minds Biosciences 

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Epilepsy Current Treatment Patterns

4. Epilepsy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Epilepsy Late Stage Products (Phase-III)

7. Epilepsy Mid-Stage Products (Phase-II)

8. Epilepsy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Epilepsy Discontinued Products

13. Epilepsy Product Profiles

14. Key Companies in the Epilepsy Market

15. Key Products in the Epilepsy Therapeutics Segment

16. Dormant and Discontinued Products

17. Epilepsy Unmet Needs

18. Epilepsy Future Perspectives

19. Epilepsy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/